Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Abbott Laboratories (ABT) — XLV Health Care · S&P 500 Profile |亞培介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Abbott Laboratories (ABT) — Business, History & S&P 500 Profile | 亞培

Abbott Laboratories company profile · business segments · history · financial snapshot · S&P 500 rank #68 · 雅培公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (ET) close
Financials: FY2024
MARKET CAP
$180.95B
Oct 29, 2026 close
S&P 500 WEIGHT
0.26%
Rank #68 · Oct 29, 2026
SECTOR RANK
#9
Health Care · Oct 29, 2026
S&P 500 RANK
#68
0.26% · Oct 29, 2026

SNAPSHOT

TickerABT
CompanyAbbott Laboratories
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#68 · 0.26% (Oct 29, 2026)
Sector rank#9 in Health Care (Oct 29, 2026)
HeadquartersAbbott Park, Illinois
Founded1888
CEORobert B. Ford
EmployeesApproximately 114,000 (Dec 31, 2024)
Market cap$180.95B (Oct 30, 2026)
Share price$106.20 (Oct 30, 2026 close)
SEC filingsEDGAR — CIK 0000001800

WHAT IT DOES

Abbott sells medical devices, diagnostics, nutritionals and branded generic pharmaceuticals worldwide.

Its diabetes care business, built around FreeStyle Libre continuous glucose monitors, is the largest growth engine.

Diagnostics spans laboratory, molecular and rapid tests, while nutritionals include Similac and Ensure.

BUSINESS SEGMENTS

Established Pharmaceutical ProductsBranded generic medicines sold mainly outside the United States. FY2024 net sales $5,194M.
Medical DevicesDiabetes care, cardiovascular and neuromodulation devices. FY2024 net sales $18,986M.
DiagnosticsLaboratory, molecular and rapid diagnostic tests. FY2024 net sales $9,341M.
NutritionalsPediatric and adult nutrition products including Similac and Ensure. FY2024 net sales $8,413M.

HISTORY

YearMilestone
1888Wallace C. Abbott founds the Abbott Alkaloidal Company in Chicago.
1900The company incorporates as Abbott Laboratories.
2013Abbott spins off its research-based pharmaceuticals business as AbbVie.
2017Abbott completes the acquisitions of St. Jude Medical and Alere.

COMPETITIVE POSITION

  • FreeStyle Libre sensors
  • Similac and Ensure nutritionals
  • Alinity laboratory systems
  • CardioMEMS heart-failure sensors
  • MitraClip structural-heart devices

FINANCIAL SNAPSHOT

Total revenue$44.33B (FY2025 net sales)
Operating income$8.05B (FY2025 operating earnings)
Net income$6.52B (FY2025 net earnings)
Diluted EPS$3.72 (FY2025 GAAP diluted EPS)
Source: Abbott Laboratories Form 10-K for the year ended December 31, 2025 (net sales $44.33B; operating earnings $8.05B; net earnings $6.52B; GAAP diluted EPS $3.72).

KEY RISKS

  • FreeStyle Libre faces competition from Dexcom and Medtronic in continuous glucose monitoring.
  • Diagnostics demand can swing with public-health and testing cycles.
  • Foreign-exchange moves weigh on a business that earns most revenue outside the United States.
  • Device and diagnostics regulation, including FDA clearance cycles, can delay launches.
  • Pricing pressure from hospitals and government payers persists across the portfolio.

WHY IT MATTERS FOR THE S&P 500

Abbott pairs a diversified health-care portfolio with a fast-growing diabetes platform: FreeStyle Libre gives the company a recurring sensor franchise, while nutritionals and diagnostics add cash-generating breadth. The risk is a single-product concentration in diabetes growth expectations.

SOURCES & METHODOLOGY

Financials, segments, headquartersAbbott Laboratories Form 10-K for the year ended December 31, 2024 (net sales $41.95B; operating earnings $6.83B; net earnings $13.40B; GAAP diluted EPS $7.64).
Index weight & ranksSlickcharts S&P 500 weights, Oct 29, 2026 close, fetched Oct 30, 2026
Market cap$180.95B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

ABT

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號ABT
公司雅培實驗室
GICS 板塊/行業健康護理(XLV)/醫療保健設備
標普500排名(按權重)#68 · 0.26%(Oct 29, 2026)
板塊內排名健康護理 #9(Oct 29, 2026)
總部伊利諾伊州亞培園
成立1888 年
執行長羅伯特·B·福特
員工約 114,000 人(2024 年 12 月 31 日)
市值$180.95B(Oct 30, 2026)
股價$106.20(Oct 30, 2026 收盤)
SEC 申報EDGAR — CIK 0000001800

業務概覽

雅培在全球銷售醫療器械、診斷產品、營養品及品牌仿製藥。

其糖尿病護理業務以 FreeStyle Libre 連續血糖監測儀為核心,是最大的增長引擎。

診斷業務涵蓋實驗室、分子與快速檢測;營養品包括 Similac 與 Ensure。

業務板塊

成熟醫藥產品主要在美國以外銷售的品牌仿製藥。 2024 財年淨銷售額 51.94 億美元。
醫療器械糖尿病護理、心血管與神經調節器械。 2024 財年淨銷售額 189.86 億美元。
診斷實驗室、分子與快速診斷檢測。 2024 財年淨銷售額 93.41 億美元。
營養品包括 Similac 與 Ensure 的兒科與成人營養產品。 2024 財年淨銷售額 84.13 億美元。

歷史沿革

年份里程碑
1888 年華萊士·C·雅培在芝加哥創立 Abbott Alkaloidal Company。
1900 年公司改組為 Abbott Laboratories。
2013 年雅培分拆研究型製藥業務為 AbbVie。
2017 年雅培完成收購聖猶達醫療(St. Jude Medical)與 Alere。

競爭地位

  • FreeStyle Libre 感測器
  • Similac 與 Ensure 營養品
  • Alinity 實驗室系統
  • CardioMEMS 心衰感測器
  • MitraClip 結構性心臟器械

財務快照

總收入$44.33B(FY2025 淨銷售額)
營業利潤$8.05B(FY2025 營業利潤)
淨利潤$6.52B(FY2025 淨利潤)
稀釋 EPS$3.72(FY2025 GAAP 攤薄每股收益)
來源:雅培截至 2025 年 12 月 31 日年度之 Form 10-K(淨銷售額 443.3 億美元;營業利潤 80.5 億美元;淨利潤 65.2 億美元;GAAP 攤薄每股收益 3.72 美元)。

主要風險

  • FreeStyle Libre 在連續血糖監測領域面對 Dexcom 與 Medtronic 的競爭。
  • 診斷需求可能隨公共衛生與檢測週期波動。
  • 匯率波動影響以美國以外收入為主的業務。
  • 醫療器械與診斷的監管(包括 FDA 審批週期)可能延遲新品上市。
  • 醫院與政府付款方的定價壓力持續存在於整個組合。

對標普500的重要性

雅培以多元化的醫療保健組合搭配快速增長的糖尿病平台:FreeStyle Libre 提供經常性感測器業務,營養品與診斷則帶來產生現金的廣度。風險在於糖尿病增長預期集中於單一產品線。

來源與方法

財務、板塊、總部雅培截至 2024 年 12 月 31 日年度之 Form 10-K(淨銷售額 419.5 億美元;營業利潤 68.3 億美元;淨利潤 134.0 億美元;GAAP 攤薄每股收益 7.64 美元)。
指數權重與排名Slickcharts S&P 500 權重,Oct 29, 2026 收盤,Oct 30, 2026 抓取
市值$180.95B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

ABT

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · ABT
Data as of Oct 29, 2026 · Financials FY2024 (10-K) · Market data Oct 2026
Previous · ConocoPhillips (COP) — XLE Energy · S&P 500 Profile |康菲石油介紹Next · Newmont Corporation (NEM) — XLB Materials · S&P 500 Profile |紐蒙特介紹

Entered 2026-10-30 05:17 · updated 2026-11-14 22:51 · rev 9